June 23rd 2021, 4:01pm
A report from Xcenda showed that biosimilars for 8 blockbuster reference biologics have successfully kept drug prices from increasing by an average of 56%, restoring the possibility that biosimilars could achieve significant discounts despite facing several barriers to uptake.
June 23rd 2021, 1:00pm
One-third of health care in the United States is wasted. Despite this recognition, solutions are sparse. The Optimal Care model combines evidence-based medicine, patient-centered technology, and outcomes reporting to transform health care.
June 18th 2021, 12:15pm
The Medicare Payment Advisory Commission (MedPAC) suggested several changes to Medicare Advantage (MA) plan benchmark calculations, with the intent to generate yield savings for Medicare, and urged CMS to streamline alternative payment model (APMs) where it can.
June 17th 2021, 4:23pm
In a 7 to 2 decision, the Supreme Court ruled Thursday that the Affordable Care Act (ACA) will stand, as plaintiffs seeking to declare the law unconstitutional did not have standing.
June 15th 2021, 1:00pm
This study evaluated cost and utilization attributed to members enrolled in a health care program with no pharmacy co-pay. Health care savings were identified in addition to medication adherence improvements.
May 13th 2021, 4:00pm
Policy makers and health plans seek value-based management of specialty drugs. This study examines real-world factors that favor some approaches over others and their potential impact.
May 7th 2021, 1:00pm
The frequency of low-value care can be reduced by a respectful, data-driven process anchored in nonjudgmental communication and explicit core values.
May 1st 2021, 12:30pm
Although the Center for Medicare and Medicaid Innovation (CMMI) has delayed the start of payment models for kidney care, one dialysis provider says it remains committed to the concept.
April 27th 2021, 1:00pm
The summit will address priority patient inputs for comparative effectiveness research and health technology assessments.
April 26th 2021, 7:15pm
Quantifying the return on investment came up for both those implementing an oncology care pathway (as a potential barrier) as well as for payers still not convinced it is a way to go.
